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Abstract
Aims/hypothesis Oxidation of LDL in the arterial extracel-
lular matrix is a key event in the development of
atherosclerosis and autoantibodies against oxidised LDL
antigens reflect disease severity and the risk of developing
acute cardiovascular events. Since type 2 diabetes is
associated with increased oxidative stress, we tested the
hypothesis that autoantibodies against oxidised LDL anti-
gens are biomarkers for vascular complications in diabetes.
Methods We studied 497 patients with type 2 diabetes
without clinical signs of coronary heart disease. Oxidised
LDL autoantibodies were determined by ELISA detecting
IgG and IgM specific for native and malondialdehyde
(MDA)-modified apolipoprotein B-100 peptides p45 and
p210. The severity of coronary disease was assessed as the
coronary artery calcium score.
Results Patients affected by retinopathy had significantly
higher levels of IgG against MDA-p45 and MDA-p210.
In contrast, high levels of autoantibodies against the
corresponding native peptides were associated with less
coronary calcification and a lower risk of progression of
coronary disease.
Conclusions/interpretation Our observations suggest that
LDL oxidation is involved in the pathogenesis of diabetic
retinopathy and that autoantibodies against apolipoprotein
B peptides may act as biomarkers for both micro- and
macrovascular complications in diabetes.
Keywords Antibodies.Low-densitylipoprotein.
Oxidation.Peripheralneuropathy.Retinopathy
Abbreviations
Apo Apolipoprotein
CAC Coronary artery calcium
CRP C-reactive protein
MDA Malondialdehyde
MPS Myocardial perfusion scintigraphy
IMT Intima–media thickness
Diabetologia (2009) 52:1426–1433
DOI 10.1007/s00125-009-1377-9
G. N. Fredrikson: R. Alm: E. Bengtsson: J. Nilsson (*)
Department of Clinical Sciences, Malmö University Hospital,
Lund University,
CRC Entrance 72, 91:12,
205 02 Malmö, Sweden
e-mail: jan.nilsson@med.lu.se
G. N. Fredrikson
Department of Biomedical Laboratory Science and Technology,
Malmö University,
Malmö, Sweden
D. V. Anand: A. Lahiri
Cardiac Imaging and Research Center, Wellington Hospital,
London, UK
D. Hopkins
Department of Diabetic Medicine, King’s College Hospital,
London, UK
R. Corder
William Harvey Research Institute,
London, UK
P. K. Shah
Atherosclerosis Research Center and Division of Cardiology,
Cedars-Sinai Medical Center,
Los Angeles, CA, USA
P. K. Shah
David Geffen School of Medicine, UCLA School of Medicine,
Los Angeles, CA, USAIntroduction
The role of immune responses against modified self-
antigens in atherosclerosis has attracted increasing attention
during recent years [1, 2]. Hypercholesterolaemic mice
deficient in components of the innate [3, 4] and adaptive
[5–8]i m m u n es y s t e m sa r eg e n erally characterised by
decreased plaque formation, suggesting that immune
responses against self-antigens modified by hypercholester-
olaemia are pro-atherogenic. Oxidised LDL is considered
the most important self-antigen generated by hypercholes-
terolaemia and autoantibodies against oxidised LDL are
abundant in both hypercholesterolaemic animals and in
humans [9–11]. However, unexpected findings of decreased
atherosclerosis development in hypercholesterolaemic ani-
mals immunised with oxidised LDL have demonstrated that
atheroprotective immune responses also exist [12–16].
Collectively, these studies imply that the initiation and
progression of atherosclerosis is modulated by the balance
between protective and pro-atherogenic immunity [17].
The immunogenic properties of oxidised LDL depend on
the formation of oxidised phospholipids, fragmentation of the
LDL protein apolipoprotein (Apo) B-100 and the aldehyde
modification of these Apo B fragments [10, 18]. We have
previously identified several native and aldehyde-modified
ApoB peptide sequences that are targeted by autoimmune
responses in humans [19]. Immune responses against the
ApoB amino acids 661–680 (p45) and 3136–3155 (p210)
have been found to be of particular importance and pilot
vaccines based on these peptides significantly inhibit the
development of atherosclerosis in experimental animals [20,
21]. People with high levels of IgG against the native forms
of p45 [22] and p210 [23] have a lower risk of development
of acute myocardial infarction, whereas high levels of IgM
against aldehyde-modified p45 and p210 are associated with
more advanced carotid atherosclerosis [19, 24]. An inverse
relation between IgG against native p210 and the severity of
coronary atherosclerosis has also been reported recently [23].
Type 2 diabetes is associated with both increased vascular
oxidative stress and the presence of LDL with increased
susceptibility to oxidation [25]. However, the possible
relations between autoimmune responses to modified self-
antigens in oxidised LDL and vascular disease in diabetes
remain largely unexplored. The aim of the present study was
to determine whether there is an association between
autoantibodies against the ApoB antigens p45 and p210
and vascular complications in patients with type 2 diabetes.
Methods
Patients The participants in the present analysis were
derived from a cohort of type 2 diabetic patients without
history or symptoms of coronary heart disease who were
participating in a study of the ability of coronary calcium
score to predict silent myocardial ischaemia and short-term
cardiovascular events [26]. Patient recruitment, inclusion
and exclusion criteria have been reported previously [26].
The study patients were prospectively recruited from four
diabetes clinics in secondary care. The study was approved
by the local research ethics committees of participating
institutions and the Administration of Radioactive Sub-
stances Advisory Committee and all participants gave
informed consent. A total of 510 individuals were prospec-
tively enrolled in the study. Symptoms of peripheral
neuropathy were recorded and sensation (using a 10 g
monofilament) and knee and ankle reflexes were assessed.
Retinopathy was assessed by annual retinal examination
according to national guidelines [27]. Fasting blood and
urine samples were obtained for DCCT-aligned HbA1c,
lipid profile, urea, creatinine and the urine albumin/
creatinine ratio. Microalbuminuria was defined as a urine
albumin/creatinine ratio >2.5 mg/mmol for men and
>3.5 mg/mmol for women.
Coronary calcium imaging and myocardial perfusion
scintigraphy The protocol for coronary artery calcium
(CAC) imaging and myocardial perfusion scintigraphy
(MPS) have been described previously [28]. In the present
study CAC scores were classified into two categories: low
to moderate coronary calcification (≤400 Agatston units)
and severe to extensive (>400 Agatston units) [28, 29].
MPS was performed according to a 2 day stress–rest
99mTc-sestamibi protocol using symptom-limited treadmill
exercise.
ELISA against the malondialdehyde-modified ApoB-100
peptide Polypeptide corresponding to the amino acids 661–
680 in human ApoB-100 (p45; IEIGLEGKGFEPT
LEALFGK) and the 3136–3155 amino acid sequence of
human ApoB-100 (p210; KTTKQSFDLSVKAQYKK
NKH) were synthesised (KJ Ross Petersen, Horsholm,
Denmark) and modified by 0.5 mol/l malondialdehyde
(MDA) for 3 h at 37°C. They were subsequently used in
ELISAs for the determination of peptide-specific anti-
bodies, as described previously [19].
Statistical analysis Differences regarding baseline charac-
teristics were tested with the t and χ
2 tests, as applicable.
Skewed variables were log-transformed before statistical
tests. Student’s t test was used to test for the significance of
differences between group means. Spearman correlation
coefficients were used to examine relationships among
continuous variables. A logistic regression model was used
to determine independent associations of various risk
factors with retinopathy, peripheral neuropathy and coro-
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Results
The patients included in the present analysis were recruited
from a cohort of patients with type 2 diabetes participating
in a study of the ability of coronary calcium score to predict
silent myocardial ischaemia and short-term cardiovascular
events [26]. Of the original 510 individuals enrolled, 13
were excluded from the present study because plasma
samples were no longer available. Of the remaining 497
diabetic patients, 114 (22.9%) had retinopathy, 90 (18.1%)
had peripheral neuropathy and 71 (14.4%) had micro-
albuminuria. Since patients with clinically manifest coro-
nary artery disease, cerebrovascular disease or peripheral
artery disease were excluded from the initial study, we used
coronary calcium scores and ischaemia as assessed by
myocardial perfusion scintigraphy as surrogate markers for
diabetic macrovascular complications. The clinical charac-
teristics of the study cohort have been published previously
[26, 30].
Autoantibodies against native and MDA-modified ApoB
peptides p45 and p210 were detected by custom-made
ELISAs. The highest antibody levels were found against
the p210 peptide. Antibody levels against MDA-modified
peptides were generally higher than against the
corresponding native peptide. This was particularly evident
for p210, for which both IgG and IgM levels were threefold
higher for the MDA peptide (Fig. 1).
Autoantibodies against ApoB peptides and microvascular
complications Patients with retinopathy had significantly
higher levels of IgG against MDA-p45 and MDA-p210
than patients without retinopathy (Fig. 2). They also had
significantly higher levels of IgG against native p210 and a
similar trend could be observed for IgG against native p45
(Fig. 2). There were no differences in p45 or p210 IgM
levels between patients with and without retinopathy (data
not shown). Compared with patients without retinopathy,
patients who had developed retinopathy were older, had a
longer duration of diabetes, increased HbA1c,h a da
moderately elevated HDL-cholesterol level and were more
frequently on insulin treatment (Table 1). When all of these
variables were entered into a logistic regression model,
MDA-p210 IgG (β coefficient 1.98, p<0.001), age
(β coefficient 0.04, p=0.005), duration of diabetes
(β coefficient 0.06, p=0.001) and HbA1c level (β coeffi-
cient 0.22, p=0.001) remained as independent predictors of
the presence of retinopathy. To further control for the
possible influence of the duration of diabetes we restricted
the analysis to subjects with duration of disease less than
10 years (n=333). Increased levels of MDA-p210 IgG were
found in patients with retinopathy (n=53) also in this
subgroup (1.05±0.24 vs 0.89±0.26 absorbance units,
p<0.001).
MDA-p210 IgG levels increased with age, blood
pressure and LDL level (Table 2). High levels of MDA-
p210 IgG were also associated with low triacylglycerol and
HDL-cholesterol levels, unexpectedly suggesting that anti-
body levels are increased in states of good metabolic
control. However, there was no association between the
MDA-p210 IgG and HbA1c level or the duration of
diabetes.
Fig. 1 Box plots showing plasma levels (absorbance [abs] units
measured at 405 nm) of a IgG and b IgM against native and MDA-
modified ApoB peptides p45 and p210 in the study cohort
Fig. 2 Box plots showing plasma levels of IgG (absorbance [abs]
units measured at 405 nm) against a native p45, b MDA-p45, c native
p210 and d MDA-p210 in diabetic individuals with and without
retinopathy. †p<0.1, *p<0.05, **p<0.01, ***p<0.001
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ropathy had higher levels of MDA-p210 IgG than patients
without signs of neuropathy (1.02±0.26 vs 0.89±0.27
absorbance units, p<0.001), whereas there were no differ-
ences between patients with or without neuropathy for any
of the other ApoB peptide autoantibodies analysed. Patients
with neuropathy were also characterised by a longer
duration of diabetes and were more often on insulin
treatment than patients without neuropathy (Table 3). When
duration of diabetes, insulin treatment and MDA-p210 IgG
were entered into a logistic regression model, only MDA-
p210 IgG remained as an independent predictor of the
presence of neuropathy. When the analysis was restricted to
individuals with a duration of diabetes of less than 10 years,
increased levels of MDA-p210 IgG were found in patients
with neuropathy (n=54; 1.05±0.22 vs 0.89±0.27 absor-
bance units, p<0.001).
There were no differences in autoantibodies against p45
and p210 in patients with or without microalbuminuria.
Autoantibodies against ApoB peptides and coronary heart
disease Patients were stratified as having low to moderate
(≤400 Agatston units, n=438) or severe to extensive
(>400 Agatston units, n=59) coronary calcification [28].
Patients with low to moderate coronary calcification had
higher plasma levels of both IgG and IgM against native
p45 (0.26±0.31 vs 0.19±0.23 absorbance units, p<0.05,
and 0.062±0.11 vs 0.048±0.111 absorbance units, p=
0.005, respectively) and native p210 (0.29±0.174 vs 0.24±
0.14 absorbance units, p<0.01, and 0.48±0.24 vs 0.39±
0.18 absorbance units, p=0.005, respectively; Fig. 3).
When we controlled for age, systolic blood pressure,
duration of diabetes, LDL cholesterol, HDL cholesterol,
triacylglycerol and HbA1c in a logistic regression analysis,
Variable Antibody
p45 MDA-p45 P210 MDA-p210
Age (years) −0.01 0.03 0.06 0.12**
Duration of diabetes (years) 0.04 0.01 0.01 −0. 05
HbA1c (%) 0.05 −0.01 −0.02 −0.07
BMI (kg/m
2) −0.06 −0.02 0.01 0.02
Systolic BP (mmHg) 0.03 0.04 0.02 0.09*
Diastolic BP (mmHg) 0.07 0.07 0.02 0.13†
Total cholesterol (mmol/l) 0.00 0.02 0.00 0.08
LDL-cholesterol (mmol/l) 0.02 0.01 0.05 0.11*
HDL-cholesterol (mmol/l) −0.02 0.03 0.12* 0.16**
Triacylglycerol (mmol/l) 0.01 0.33 −0.16† −0.14†
C-reactive protein (mg/l) 0.01 0.01 0.01 −0.01
Table 2 Correlations between
risk factors and plasma levels
of IgG against p45 and p210
Values are Spearman rank cor-
relation coefficients
*p<0.05; **p<0.01; †p<0.005
Characteristic No retinopathy (n=383) Retinopathy (n=114) p value
Age 52.2 ± 8.2 55.2 ± 8.3 <0.001
Male sex (%) 60.6 61.4 0.87
Duration of diabetes (years) 7.4 ± 5.7 10.4 ± 6.5 <0.001
HbA1c (%) 8.1 ± 1.6 8.6 ± 1.6 0.001
BMI (kg/m
2) 28.5 ± 4.8 28.5 ± 5.4 0.97
Systolic BP (mmHg) 136 ± 16 138 ± 18 0.29
Diastolic BP (mmHg) 83 ± 12 85 ± 14 0.15
Total cholesterol (mmol/l) 4.8 ± 0.9 4.8 ± 1.0 0.99
LDL-cholesterol (mmol/l) 2.7 ± 0.8 2.7 ± 0.9 0.94
HDL-cholesterol (mmol/l) 1.2 ± 0.4 1.4 ± 0.4 0.019
Triacylglycerol (mmol/l) 1.9 ± 1.1 1.8 ± 1.2 0.33
C-reactive protein (mg/l) 8.2 ± 33.2 8.1 ± 14.8 0.98
Current smokers (%) 20.9 14.0 0.17
Insulin therapy (%) 18.5 29.8 0.01
Statin therapy (%) 39.9 36.8 0.55
Table 1 Clinical characteristics
of diabetic patients with and
without retinopathy
Values are mean ± SD or
percentage
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dently associated with the severity of coronary calcification.
Follow-up CAC imaging was performed in 398 participants
(age 52±8 years, 61% male, HbA1c 8±1.5%) [30]. The
mean follow-up time was 2.5±0.4 years. Progression of
CAC was defined as a change of ≥2.5 between the square
root-transformed values of baseline and follow-up volu-
metric scores. Patients with coronary calcium progression
(n=119) had lower plasma levels of IgG against native p45
than patients without progression (0.19±0.21 vs 0.29±0.33
absorbance units, p<0.001), whereas there was no associ-
ation between antibodies against p210 and CAC progres-
sion. Native p210 IgG levels were significantly related to
higher HDL-cholesterol and lower triacylglycerol levels,
suggesting an association with good metabolic control,
whereas there was no significant association between IgG
against native p45 and age or metabolic measurements
(Table 2).
During the follow-up studies, 20 events occurred (three
cardiac deaths, nine non-fatal myocardial infarctions, three
non-haemorrhagic strokes, four late revascularisations and
one below knee amputation) [30]. No differences were
observed in antibody levels between patients who suffered
from a cardiovascular event and those who remained event-
free (data not shown). MPS data were available for 174
patients. There were no significant differences in antibody
levels among patients with normal myocardial perfusion
and those with varying degrees of myocardial ischaemia
(data not shown).
Discussion
In the present study we found increased levels of IgG
against the MDA-modified ApoB epitopes p45 and p210 in
type 2 diabetes patients suffering from retinopathy and
peripheral neuropathy. This suggests that oxidation of LDL
may be involved in the development of diabetic microvas-
cular complications and that autoantibodies against MDA-
Fig. 3 Box plots showing plasma levels of a IgG against (absorbance
[abs] units measured at 405 nm) native p45, b IgM against native p45,
c IgG against native p210 and d IgM against native p210 in diabetic
individuals with low to moderate (≤400 Agatston units) and severe
to extensive (>400 Agatston units) coronary calcification. *p<0.05,
**p<0.01, ‡p=0.005
Characteristic No neuropathy (n=407) Neuropathy (n=90) p value
Age (years) 52.4±8.5 53.9±7.9 0.14
Male sex (%) 60.4 62.2 0.75
Duration of diabetes (years) 7.8±5.7 9.2±7.1 0.04
HbA1c (%) 8.2±1.8 8.2±1.5 0.73
BMI (kg/m
2) 28.3±4.8 29.4±5.6 0.06
Systolic BP (mmHg) 137±16 136±18 0.52
Diastolic BP (mmHg) 83±12 85±13 0.18
Total cholesterol (mmol/l) 4.8±0.9 4.8±0.9 0.56
LDL-cholesterol (mmol/l) 2.7±0.8 2.8±0.7 0.48
HDL-cholesterol (mmol/l) 1.3±0.4 1.3±0.4 0.63
Triacylglycerol (mmol/l) 1.9±1.1 1.9±1.3 0.64
C-reactive protein (mg/l) 8.6±33.9 6.2±7.5 0.50
Current smokers (%) 18.9 21.1 0.56
Insulin therapy (%) 18.7 47.5 0.004
Statin therapy (%) 38.8 41.1 0.69
Table 3 Clinical characteristics
of diabetic patients with and
without peripheral neuropathy
Values are mean ± SD or
percentage
1430 Diabetologia (2009) 52:1426–1433p210 represent potential biomarkers for diabetic retinopathy
and peripheral neuropathy. We also demonstrate that
individuals with high antibody levels against the native
form of these peptides have less coronary calcification as
well as less progression of coronary disease. This observa-
tion is well in line with previous studies demonstrating a
lower cardiovascular risk in patients with high levels of
autoantibodies against native ApoB peptides [22, 23]. Our
findings provide evidence for a role of immune responses
against LDL-associated antigens in diabetic complications
but suggest that these may be different between micro- and
macrovascular complications.
The possibility that oxidation of lipoproteins entrapped
in the extracellular matrix of retinal vessels may contribute
to the development of diabetic retinopathy remains largely
unexplored. Oxidised LDL is proinflammatory and poten-
tially cytotoxic for endothelial cells [31, 32]. It may also
activate autoimmune responses that cause further damage to
the affected tissue [1]. Dysregulation of lipoprotein metab-
olism in type 2 diabetes leads to the formation of small,
dense LDL particles with increased susceptibility to
oxidation [33]. Accordingly, the present observation of
increased levels of autoantibodies against the oxidised
LDL-specific antigens MDA-p45 and MDA-p210 in
patients with diabetic retinopathy is compatible with the
notion that the combination of increased retinal endothelial
oxidative stress and the presence of LDL particles with
increased oxidation susceptibility contributes to increased
local oxidation of LDL. This possibility is in line with
epidemiological data demonstrating that hyperlipidaemia
increases the risk of development of maculopathy in diabetes
and with the observation that statin therapy may protect
against the development of age-related macular degeneration
[34–36]. The possibility that autoimmune responses against
modified self-antigens in oxidised LDL is of functional
importance for the development of diabetic retinopathy
requires evaluation in appropriate animal models.
Diabetic neuropathy has many different clinical mani-
festations and is one of the most common complications of
diabetes [37]. Like proliferative retinopathy, its severity
parallels the degree and duration of hyperglycaemia and the
pathophysiology is believed to involve increased intracel-
lular stress. Its possible association with LDL oxidation
remains essentially unexplored. Again, the present obser-
vations argue that this concept should be explored in
appropriate animal models.
Another possibility is that the elevated levels of MDA
ApoB peptide autoantibodies in patients with diabetic
retinopathy and peripheral neuropathy only act as markers
of the disease. There are relatively few studies of the
association of oxidised LDL autoantibodies with diabetes
and its complications. Festa et al. [38] have reported
increased anti-oxidised LDL IgG levels in patients with
type 1 diabetes compared with controls, but also that
antibody levels were decreased in patients with a long
duration of diabetes and high HbA1c levels. The latter
observation was explained by increased formation of
oxidised LDL-specific immune complexes. An increased
level of oxidised LDL-specific immune complexes has also
been linked to both micro- and macrovascular complica-
tions in diabetes [39–41].
The associations between oxidised LDL autoantibodies
and cardiovascular disease have been extensively studied
but with inconsistent results [42–47]. The reason for this
remains to be elucidated but may involve technical
difficulties in standardising ELISAs based on a complex
and poorly defined antigen such as oxidised LDL. One way
of circumventing this problem has been to use more
precisely characterised oxidised LDL antigens such as
native and MDA-modified peptide fragments of ApoB
[19]. The limitation of this approach is that only some of
the antibodies generated against oxidised LDL are detected,
but at the same time it offers the advantage of improved
specificity and reproducibility. Here we demonstrate that
high antibody levels against the native p45 and p210 ApoB
peptides are associated with less severe coronary calcifica-
tion. Moreover, we show that patients with high baseline
plasma levels of native p45 IgG have reduced progression
of coronary calcification. These observations are in good
agreement with previous studies demonstrating that indi-
viduals with high levels of IgG against native p45 and p210
are at lower risk of developing acute cardiovascular events
[22, 23]. An inverse association has also been found
between IgG against native p210 and coronary atheroscle-
rosis [23]. Studies evaluating the functional role of immune
responses against native ApoB peptides have shown that
immunisation of hypercholesterolaemic mice with the p45
and p210 peptides inhibits the development of atheroscle-
rosis, suggesting that it may be possible to develop ApoB
peptide-based vaccines for the prevention of cardiovascular
disease. The present observations provide some indirect
support for the notion that such vaccines could be effective
also in patients with diabetes.
There has been increasing interest in identifying novel
biomarkers that can be used to predict the risk of
development and to monitor treatment for diabetic vascular
complications. The present observations suggest that auto-
antibodies against the MDA-modified ApoB peptide p210
are possible biomarkers for diabetic retinopathy and
peripheral neuropathy, while antibodies against the
corresponding native peptides are potential biomarkers for
macrovascular complications. These possibilities need to be
addressed in appropriate animal models and in large
prospective clinical studies.
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